Cofactor Genomics Receives National Medicare Coverage for OncoPrism Predictive Diagnostic Test for Cancer Patients

Cofactor Genomics Receives National Medicare Coverage for OncoPrism, a Groundbreaking Cancer Diagnostic Test

SAINT LOUIS–(BUSINESS WIRE)–#cancer–Cofactor Genomics, Inc., a clinical-stage company specializing in decoding RNA to bridge the precision medicine gap, has just announced a major milestone. Medicare contractor Palmetto GBA has granted national coverage for OncoPrism, a solid tumor predictive diagnostic test that evaluates a patient’s tumor immune profile to predict their response to immune checkpoint inhibitor (ICI) immunotherapy.

The Medicare coverage decision specifically applies to recurrent and metastatic head and neck squamous cell carcinoma (RM-HNSCC) patients who are being considered for ICI immunotherapy treatment. This approval is a significant step forward in the field of precision medicine, as it allows for more accurate prediction of patient response and better treatment prioritization, ultimately leading to improved patient outcomes.

Jarret Glasscock, CEO of Cofactor Genomics, expressed his excitement about the Medicare coverage decision, stating, “This is a win for all those working tirelessly to bridge the precision medicine gap in immunotherapy. Most importantly, this is a win for cancer patients.”

RM-HNSCC is just one of eleven solid tumor cancers being studied in a multicenter national clinical trial called PREDAPT, which aims to evaluate OncoPrism’s ability to predict patient response to ICI. Cofactor Genomics is at the forefront of RNA modeling, with their patented Health Expression Models (HEMs) representing a groundbreaking approach to decoding RNA for healthcare applications.

Cofactor’s work in RNA modeling has been recognized in prestigious scientific journals and has been hailed as breakthrough work in the field of cancer research. Their OncoPrism test is CAP/CLIA-validated and Medicare-approved, making it a reliable and innovative tool for predicting patient response to immunotherapy.

For more information about Cofactor Genomics and their groundbreaking work in RNA-based diagnostics, visit www.cofactorgenomics.com and LinkedIn. For press inquiries, contact press@cofactorgenomics.com.